Ignite Creation Date:
2024-05-05 @ 12:07 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00258856
Status:
COMPLETED
Last Update Posted:
2014-02-14
First Post:
2005-11-24
Brief Title:
Persistence of Antibodies in Children Aged 7 to 15 Years Who Previously Received One Dose of Menactra or Menomune
Sponsor:
Sanofi Pasteur a Sanofi Company
Organization:
Sanofi
Study Overview
Official Title:
Persistence of Bactericidal Antibodies in Children Aged 7 to 15 Years Who Received a Single Dose of Menactra or Menomune-ACYW-135 Five Years Earlier
Status:
COMPLETED
Status Verified Date:
2014-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study is designed to evaluate the persistence of bactericidal antibodies in subjects aged 7 to 15 years not yet 16 years who had been vaccinated five years previously in Study 603-02 In addition the kinetics of the antibody response will be evaluated in a subset of participants who will receive a booster dose of Menactra vaccine and children in the same age group not previously vaccinated with a meningococcal vaccine or had meningitis disease who will receive a dose of Menactra vaccine
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None